Estimating the sensitivity and specificity of matching name-based with non-name-based case registries.

Because non-name-based case registries have recently been used for reporting human immunodeficiency virus infection, this study attempted to define the sensitivity, specificity and accuracy of case registry matches using non-name-based registries. The AIDS, sexually transmitted disease (STD), and tuberculosis (TB) case registries were matched using all available information to establish the standard. The registries were then matched again using five increasingly less specific criteria to compare sensitivity, specificity and accuracy. The registries were then also transformed into non-name-based codes as if they were the HIV registry and matched again. With name-based registries, sensitivities increased as the matching criteria became less exacting, while the accuracy declined slightly. Specificities remained close to 100% due to the relatively small number of matched cases. Results from matches of non-name-based registry matches were similar to those of the name-based registry matches. Non-name reporting can be used for data matching with acceptable accuracy.

Management of urethritis in health maintenance organization members receiving care at a multispecialty group practice in Massachusetts.

BACKGROUND: Cost containment has led to a concern that health maintenance organization-insured patients presenting with complaints of urethritis may be treated without being tested. GOAL: To determine the proportion of men presenting with symptoms of urethritis who are tested for Chlamydia trachomatis and Neisseria gonorrhoeae. STUDY DESIGN: Reviews were performed on 196 randomly selected patient records with an outpatient visit and a diagnostic code consistent with urethritis between 1995 and 1997. Data were collected on demographics, diagnostic testing, and treatment. RESULTS: Diagnostic testing for C trachomatis and N gonorrhoeae was performed, respectively, in 92.3% and 83.2% of the men presenting at an initial visit with complaints of urethritis. Altogether, 98.2% of the patients who met the Centers for Disease Control criteria for documenting urethritis were tested for C trachomatis and N gonorrhoeae. CONCLUSION: Diagnostic testing for C trachomatis and N gonorrhoeae is nearly universal in this multispecialty group practice setting, facilitating surveillance and public health efforts.

Neonatal chlamydial infections in Massachusetts, 1992-1993.

INTRODUCTION: An increase in the numbers of babies reported with Chlamydia trachomatis infections in Massachusetts prompted a review of the medical records of both infants and mothers to evaluate the clinical presentation, the maternal epidemiologic profile, risks of transmission, and the screening practices of health care providers. METHODS: Medical records of 44/47 infants reported with a chlamydial infection in 1992-1993 were analyzed, as were 40 of the maternal records. RESULTS: Almost all of the infants (39, or 89%) had conjunctivitis, despite the fact that ocular prophylaxis with erythromycin was documented at birth for 34 infants. Five other infants presented with respiratory tract infections without conjunctivitis, and they had all received prophylaxis at birth either with erythromycin (3) or silver nitrate instillation (2). More than one fifth (10, or 22.7%) had a respiratory tract infection. Seventy percent of the mothers were younger than 25. More than 85% were receiving prenatal care by the end of the second trimester. Twenty-five (62.5%) were screened for chlamydia. Nine women tested positive, seven of whom were tested beyond the first trimester. Seventy-five percent of the women who tested negative were tested in the first trimester. DISCUSSION: This case series supports previous data documenting that ocular prophylaxis can fail to prevent neonatal chlamydial conjunctivitis, and does not prevent colonization or infection at other sites. This study reinforces the importance of primary prevention of neonatal infections through prenatal screening in the third trimester, treatment of infected mothers and their sexual partner(s), and active follow-up.